Despite strong clinical data, RSV immunization rates among pregnant women and older adults remain worryingly low, ...

NHS England » NHS to roll out long-lasting ‘suit of armour’ jab to protect thousands of premature babies from RSV ...

Despite adequate availability of nirsevimab, only about one third of eligible children receive it for respiratory syncytial virus prophylaxis, with uptake varying by race and other social factors.

The risk for severe RSV-related outcomes was effectively reduced among children and infants who received nirsevimab in real-world clinical settings.

Despite near universal availability of nirsevimab, only 35% of eligible children receive nirsevimab for RSV prophylaxis.

Vulnerable premature babies who need extra protection against RSV may receive six months’ protection in a long-lasting single ...

John Stewart, Director of Specialised Commissioning at NHS England said: “For babies born very prematurely, the risk of ...

A new antibody shot that protects babies against RSV infection could be struggling to gain traction, Philadelphia researchers ...

Respiratory Syncytial Virus (RSV) is the leading cause of hospitalization in all infants. 1-5 Nirsevimab is being investigated as a first-in-class single dose immunization to provide protection ...

Nirsevimab, a monoclonal antibody recently approved to prevent respiratory syncytial virus-associated lower respiratory disease in newborns and infants, may protect longer than an RSV season ...

An RSV vaccine has been available to pregnant women in Northern Ireland since last September and is offered from 28 weeks of ...

Sanofi will host a nirsevimab R&D investor event today at 5 p.m. CET/11 a.m. ET PARIS – July 30, 2020 – Detailed results from the positive Phase 2b trial for nirsevimab showed a significant ...